GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Interest Coverage

Radiopharm Theranostics (ASX:RAD) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Radiopharm Theranostics's Operating Income for the six months ended in Dec. 2024 was A$-19.81 Mil. Radiopharm Theranostics's Interest Expense for the six months ended in Dec. 2024 was A$-0.49 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Radiopharm Theranostics's Interest Coverage or its related term are showing as below:


ASX:RAD's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 118.745
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Radiopharm Theranostics Interest Coverage Historical Data

The historical data trend for Radiopharm Theranostics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Radiopharm Theranostics Interest Coverage Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Interest Coverage
- - -

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial - - - - -

Competitive Comparison of Radiopharm Theranostics's Interest Coverage

For the Biotechnology subindustry, Radiopharm Theranostics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Interest Coverage falls into.


;
;

Radiopharm Theranostics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Radiopharm Theranostics's Interest Coverage for the fiscal year that ended in Jun. 2024 is calculated as

Here, for the fiscal year that ended in Jun. 2024, Radiopharm Theranostics's Interest Expense was A$-0.64 Mil. Its Operating Income was A$-36.62 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

Radiopharm Theranostics did not have earnings to cover the interest expense.

Radiopharm Theranostics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Radiopharm Theranostics's Interest Expense was A$-0.49 Mil. Its Operating Income was A$-19.81 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

Radiopharm Theranostics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Radiopharm Theranostics  (ASX:RAD) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Radiopharm Theranostics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Radiopharm Theranostics Headlines

No Headlines